Patents by Inventor ZARIFE SAHENK

ZARIFE SAHENK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and materials for NT-3 gene therapy
    Patent number: 11926653
    Abstract: The present disclosure relates to recombinant adeno-associated vims (rAAV) delivery of a neurotrophin 3 (NT-3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for NT-3 gene therapy to improve muscle strength, stimulate muscle growth and to treat muscle wasting disorders, such as muscular dystrophy and Charcot-Marie-Tooth neuropathy.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 12, 2024
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventor: Zarife Sahenk
  • Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A
    Publication number: 20230390417
    Abstract: Products and methods for treating limb girdle muscular dystrophy 2A are provided. In the methods, recombinant adeno-associated viruses deliver DNA encoding a protein with calpain 3 activity.
    Type: Application
    Filed: June 2, 2022
    Publication date: December 7, 2023
    Inventor: Zarife Sahenk
  • RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTS AND METHODS FOR TREATING LIMB GIRDLE MUSCULAR DYSTROPHY 2A
    Publication number: 20210277362
    Abstract: Products and methods for treating limb girdle muscular dystrophy 2A are provided. In the methods, recombinant adeno-associated viruses deliver DNA encoding a protein with calpain 3 activity.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 9, 2021
    Inventor: Zarife Sahenk
  • Methods and Materials for NT-3 Gene Therapy
    Publication number: 20200339960
    Abstract: The present disclosure relates to recombinant adeno-associated vims (rAAV) delivery of a neurotrophin 3 (NT-3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for NT-3 gene therapy to improve muscle strength, stimulate muscle growth and to treat muscle wasting disorders, such as muscular dystrophy and Charcot-Marie-Tooth neuropathy.
    Type: Application
    Filed: October 19, 2018
    Publication date: October 29, 2020
    Inventor: Zarife Sahenk
  • PYRUVATE COMPOUNDS FOR TREATMENT OF PERIPHERAL NEUROPATHY
    Publication number: 20180263945
    Abstract: A method of treating a subject having peripheral neuropathy is described that includes administering a therapeutically effective amount of a pyruvate compound to the subject. Controlled release formulations of a pharmaceutically acceptable pyruvate salt can be used to administer the pyruvate compound over a substantial period of time.
    Type: Application
    Filed: December 21, 2015
    Publication date: September 20, 2018
    Inventor: ZARIFE SAHENK